Zimmer Biomet is a global medical technology leader that designs, manufactures, and markets orthopedic reconstructive products, sports medicine, biologics, extremities and trauma products, craniomaxillofacial and thoracic products, surgical products, and a suite of integrated digital and robotic technologies. The company collaborates with healthcare professionals to advance innovation and provide solutions for patients with disorders or injuries to bones, joints, and soft tissues. Zimmer Biomet's products are sold through direct channels to healthcare institutions and through stocking distributors and healthcare dealers.

The company was incorporated in Delaware in 2001, with its history dating back to 1927. In 2015, Zimmer acquired LVB Acquisition, Inc., the parent company of Biomet, Inc. On March 1, 2022, Zimmer Biomet completed the spinoff of its spine and dental businesses into a new public company, ZimVie Inc.

• Employees: Approximately 18,000 worldwide (as of December 31, 2023)
• Geographic Footprint: Operates in more than 100 countries
• Headquarters: Warsaw, Indiana
• Founded: 2001 (history dates back to 1927)
• Number of manufacturing locations: Approximately 25 worldwide
• Revenue: $7.39 billion (FY2023)
• Key Subsidiaries/Brands: Persona® Knee, NexGen® Knee Implants, Vanguard® Knee, Oxford® Partial Knee, Taperloc® Hip System, Avenir Complete® Hip System, Arcos® Modular Hip System, G7® Acetabular System, JuggerKnot® Soft Anchor System, Gel-One® Cross-linked Hyaluronate, Comprehensive® Shoulder, Natural Nail® System, and SternaLock® System.

• CEO: Ivan Tornos
• CFO: Suketu Upadhyay
• Other Key Executives: Mark Bezjak (President, Americas), Rachel Ellingson (Senior Vice President and Chief Strategy Officer), Chad Phipps (Senior Vice President, General Counsel and Secretary), Paul Stellato (Vice President, Controller and Chief Accounting Officer), Wilfred van Zuilen (Group President, Europe, Middle East and Africa), Lori Winkler (Senior Vice President, Chief Human Resources Officer), and Sang Yi (Group President, Asia Pacific)

Ivan Tornos was appointed President and Chief Executive Officer in August 2023. Prior to that, he served as the Company's Chief Operating Officer since March 2021. Suketu Upadhyay was appointed Chief Financial Officer and Executive Vice President in August 2023. Previously, he served as our Executive Vice President and Chief Financial Officer since joining the Company in July 2019.

• Annual Revenue: $7.39 billion (FY2023)
• Net Income: $1.02 billion (FY2023)
• Total Assets: $21.5 billion (as of December 31, 2023)
• Number of Employees: Approximately 18,000 (as of December 31, 2023)
• Key Financial Highlights: Net sales increased by 6.5% year-over-year. Net earnings increased due to higher net sales, favorable tax settlements and lower operating expenses.

Zimmer Biomet's products include:

• Orthopedic Reconstructive Products: Knees, hips, and related surgical products.
• Sports Medicine, Biologics, Extremities and Trauma Products: Products for soft tissue repair, joint preservation, and bone stabilization.
• Craniomaxillofacial and Thoracic (CMFT) Products: Products for face, skull, and chest reconstruction.
• Surgical Products: Surgical instruments and related technologies.
• Integrated Digital and Robotic Technologies: A suite of digital and robotic technologies, including the ROSA® Robot and ZBEdge™ Platform.

Zimmer Biomet operates through three reportable segments:

• Americas: Primarily the U.S. market, also includes other North, Central and South American markets.
• EMEA: Europe, Middle East, and Africa
• Asia Pacific: Includes key markets such as Japan, China, Australia, New Zealand, and Korea.

The Americas segment accounted for approximately 95% of net sales in the region in 2023. France, Germany, Italy, Spain and the United Kingdom collectively accounted for approximately 55% of net sales in the EMEA region in 2023. Japan accounted for approximately 50% of the Asia Pacific region's sales in 2023.

Zimmer Biomet's strategy focuses on innovation, quality, and customer service. Key strategic initiatives include:

• Developing new products and technologies, including artificial intelligence and machine learning applications.
• Improving existing products and technologies.
• Expanding offerings in certain product categories.
• Enhancing commercial execution and improving supply chain efficiencies.
• Investing in research and development activities to develop new surgical techniques, materials, biologics and product designs.

Zimmer Biomet operates in the highly competitive orthopedics and broader musculoskeletal care industry. Key competitors include:

• Major Competitors: DePuy Synthes (Johnson & Johnson), Stryker Corporation, and Smith & Nephew plc.
• Market Position: The company is a leader in the global markets for knees, hips and S.E.T. products.
• Industry Trends: The industry is driven by technological advancements, innovation, and quality and is subject to pricing pressures and regulatory changes.

• Market Risks: Competition, pricing pressures, dependence on new product development, and changes in customer demand.
• Operational Risks: Supply chain disruptions, manufacturing interruptions, and integration of acquired businesses.
• Financial Risks: Substantial indebtedness, interest rate fluctuations, and changes in tax laws.
• Regulatory Risks: Compliance with governmental laws and regulations, including those of the FDA and other government regulators.
• Cybersecurity Risks: Breaches or failures of information technology systems or products, including by cyberattack, unauthorized access or theft.